The Efficacy of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Primary Hepatocellular Carcinoma in a Cohort of 487 Patients

Hui Xie1,2*, Huaming Wang2, Weimin An2, Wei Ma2, Ruping Qi2, Bin Yang2, Chunzi Liu2, Yuanzhi Gao2, Beibei Xu2, Wenhong Wang3

1 Graduate School of Tianjin Medical University, Tianjin, China, 2 Medical Imaging Center, 302 Hospital of Chinese People’s Liberation Army, Beijing, China, 3 Department of Radiology, Tianjin Union Medical Center, Tianjin, China

Abstract

Although diagnostic methods, surgical techniques, and perioperative care have undergone significant advancement over the past decades, the prognosis of primary hepatocellular carcinoma (HCC) remains discouraged because of the high postoperative recurrence rate and high cancer mortality. Radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) is a recently developed means for the treatment of HCC. In this study, we analyzed the efficacy of RFA plus TACE in 487 cases of HCC in our institution. We observed that the 1-, 2-, 3-, 4- and 5-year rates of overall survival rates after RFA and TACE treatment were 97.5% (475/487), 89.4% (277/310), 84.2% (181/215), 80.4% (150/186) and 78.7% (141/177), respectively. We did not find that age or tumor location (the caudate group or non-caudate group) plays a role in this cohort. However, we have identified that tumor recurrent status, the number of tumors, albumin (ALB), prothrombin time (PT) and platelet count (PLT) were significantly associated with poor overall survival in HCC patients receiving RFA combined with TACE. Interestingly, tumor size did not significantly impact overall survival, indicating that RFA combined with TACE for HCC treatment has the same efficiency for different sizes of tumors. Our results provide evidence for the rationale for using combined RFA and TACE in the treatment of primary HCC.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common human malignancies worldwide and has an estimated diagnosis of 750,000 new cases, with a survival rate of less than 5%, and an average survival of less than a year after diagnosis [1]. In China, HCC is the third leading cause of cancer mortality [2]. Although diagnostic methods, surgical techniques, and perioperative care have undergone significant advancement, the prognosis of HCC patients remains discouraging because of the high postoperative recurrence rate and high cancer mortality. Identifying the optimal therapy to improve outcomes for our HCC patients is therefore crucial for maximizing their long-term survival. Treatment outcomes for HCC patients are affected by multiple variables, such as tumor burden, tumor stage, the Child-Pugh score of liver function reserve and the performance status of the patient [3]. Curative therapy of HCC consists of surgical hepatic resection or liver transplantation (LT). However, liver resection can be done in noncirrhotic patients and a small fraction of cirrhotic patients depending on synthetic dysfunction, degree of portal hypertension, and number and location(s) of tumor(s) [4]. LT is the optimal therapy for patients with HCC, but the shortage of donor organs represents a major problem in applying primary transplantation to many patients. Radiofrequency ablation (RFA) is thought to be the most effective first-line percutaneous ablation technique because of its greater efficacy in terms of local cure compared with ethanol injection [5,6]. The survival rates for patients who achieved a complete response by RFA are comparable to that of patients treated by hepatic resection [7,8]. Therefore, RFA has been widely used as a first-line therapy for patients with small HCC who could not receive surgical resection or LT in the recent years [8,9,10,11].

Because HCC is also a type of vascular solid cancer, transcatheter arterial chemoembolization (TACE) and transcatheter arterial embolization (TAE) are widely used for unresectable HCC due to their precisely targeted, minimal invasive, repeatable and well-tolerated features [12,13,14,15]. However, complete necrosis is rarely achieved by TACE or TAE alone due to the incomplete embolization and tumor angiogenesis [16]. In addition, low physiological oxygen levels by TAE may lead to the accumulation of hypoxia-inducible factors and vascular endothelial growth factor (VEGF) and may induce angiogenesis in the residual viable tumor [17].

RFA or TACE has its own limitations. RFA combined with TACE in the treatment of HCC was previously reported and has shown a relatively high complete local response rate compared with TAE or RFA alone [18,19]. In the current study, we...
examined the efficacy of RFA combined with TACE for the treatment of HCC in a cohort of 487 patients.

**Materials and Methods**

This retrospective study consisted of 487 consecutive patients with solitary HCC, all of whom were treated by RFA combined with TACE in our institution between June 2006 and December 2012. HCC was diagnosed on the basis of standard clinical criteria, imaging criteria and α fetoprotein levels (AFP) according to the American Association for the Study of Liver Diseases practice guidelines on the management of HCC [20], and the diagnosis was confirmed pathologically by needle biopsy. Since World Health Organization defines age >65 years as the elderly [21], this study stratified patients aged 65 years or less as the younger group and those aged >65 years as the elderly group.

**Transcatheter Arterial Chemoembolization (TACE)**

Seldinger technology was used to puncture the femoral artery. TACE procedures were performed under radiographic guidelines following the steps that have been described elsewhere [22]. During TACE, a mixture of oxaliplatin, 5-fluorouracil and Doxorubicin was infused into tumor-feeding arteries. Then, super emulsified lipiodol (5–15 ml) was infused into same arteries. A dose of chemical drugs or lipiodol administrated was estimated according to tumor size, number, as well as angiography.

**Radiofrequency Ablation (RFA)**

About 2–4 weeks after finishing TACE treatment, all patients underwent percutaneous RFA using RF2000 radiofrequency system (USA Darrow). Ablation energy and time were determined according to the size and number of tumors in the liver. All tumors were targeted to be ablated with a curative intent in one or two sessions of RFA, with surrounding margins greater than 5 mm. Treatment response was evaluated, and no residual nodular hypervascular region was evidenced by contrast-enhanced computed tomography (CT) after one month post-RFA.

We defined recurrence as the appearance of new lesions with radiologic features typical of HCC, with diagnosis based on at least one imaging method, contrast-enhanced CT or Magnetic Resonance Imaging (MRI). The overall recurrence included tumors occurring at any time or at any site after the patients showed no active lesion at the operation site one month after one or two RFA sessions.

**Biochemical and Serologic Markers**

Serum hepatitis B surface antigen (HBsAg) was tested using radioimmunoassay (Abbott Laboratories, North Chicago, IL). Antibody to hepatitis C virus (HCV) was measured by second-generation enzyme immunoassay (Abbott Laboratories, North Chicago, IL). Serum biochemistries, including albumin, bilirubin, alanine aminotransferase, were measured using a systemic multi-auto-analyzer (Technicon SMAC, Technicon Instruments Corp., Tarrytown, NY). Serum AFP level was measured by radioimmunoassay (Serono Diagnostic SA, Coinsin/VD, Switzerland).

**Ethics Statement**

Ethical approval was obtained from the Committee of Ethics in Biomedical Research of 302 Hospital of Chinese People’s Liberation Army. Written informed consent was obtained from all participants. The research design was hospital-based and retrospective with all cases being well evaluated.

**Statistical Analysis**

GraphPad software was used for data analysis. The data was expressed as mean ± standard deviation. The difference between two groups was determined by a t-test. Pearson χ² analysis or Fisher exact test was used to compare categorical variables, whereas the Mann-Whitney U test was used to compare continuous variables. Overall survival rates were estimated by the Kaplan-Meier method and compared using Cox proportional hazards model. P values less than 0.05 were considered statistically significant.

**Results**

**Comparison of Clinical Demographic Data**

Since previous studies demonstrated that age plays an important role in the outcomes of HCC treatment, we first examined whether or not age also played a role in this cohort. The demographic characteristics of all enrolled patients are shown in Table 1. The proportion of sex distribution and background liver diseases (HBV, HCV) of patients was not significantly higher in the younger group than that in the elderly group. There were no significant differences in tumor recurrent status, tumor sizes and numbers between the two groups. In addition, we did not observe significant differences in several biochemical and serologic markers between the two groups. Thus, the overall survival rates were not significantly higher in younger HCC patients than in elderly group (Figure 1a). We also determined that the overall survival rates were not significantly correlated with body mass index (BMI) (Figure 1b).

**Factors Associated with Overall Survival After RFA and TACE for HCC**

In this study, after RFA and TACE treatment, the 1-, 2-, 3-, 4- and 5-year overall survival rates were 97.5% (475/487), 89.4% (277/310), 84.2% (181/215), 80.4% (150/186) and 78.7% (141/177), respectively. There was a total of 39 cases of death, among which 24 cases died from tumor recurrence, 8 from gastrointestinal bleeding, 3 from liver failure, 2 from hepatorenal syndrome, and 2 from liver portal vein thrombosis.

Next, we determined the factors that were associated with poor overall survival after RFA and TACE for HCC by univariate analysis (Table 2). We identified that the tumor recurrent status, number of tumors, ALB, PT and PLT were significantly associated with poor overall survival after RFA and TACE for HCC (Figure 2). Interestingly, tumor size did not significantly impact the overall survival, indicating that RFA combined with TACE for HCC treatment has the same efficiency for both small and large tumor sizes (Figure 2a).

**Comparison between the Caudate Group and the Non-caudate Group**

Finally, we determined whether or not RFA combined with TACE for HCC treatment is as effective for HCC in the caudate lobe as it is for HCC at other sites in the liver (Table 3). We did not find any significant differences of several factors between the caudate group and the non-caudate group. As expected, the overall survival rates were not significantly changed between the two groups (Figure 3).

**Discussion**

HCC is one of the most common malignant tumors in China, with the incidence rate up to 80 per million of the populations. More than 80% patients have simultaneous liver cirrhosis, which
leads to an actual rate of resection less than 30%, and the 5 year recurrence rate after resection reaches above 70% [23,24,25]. Therefore, RFA is generally considered as an alternative treatment to partial hepatectomy for early HCC, especially for patients with impaired liver function and when liver transplantation is not indicated. RFA is also recommended as a first-line treatment for early HCC [26,27,28]. TACE or TAE is another minimally invasive option that may achieve the pertinent balance in successful tumor eradication and maximal preservation of liver functions [29,30]. Theoretically, TACE that combines the effects of transcatheter arterial chemotherapy and TAE should be more effective than either alone, a meta-analysis of TACE versus TAE alone has demonstrated no survival difference [31]. RFA combined with TAE in the treatment of HCC was seldom reported, however, the synergy between RFA and TACE has been well described [18,32]. Occlusion of hepatic arterial flow by embolization reduces the cooling effects of hepatic blood flow on thermal coagulation. In addition, iodized oil and gelatin sponge particles used in TACE fill the peripheral portal vein around the tumor by going through multiple arterioportal communications, thus reducing the portal venous flow [22,23]. TACE or TAE, being a regional treatment, can target undetected satellite lesions surrounding the zone of RFA-induced necrosis. Therefore, RFA combined with TAE or TACE is increasingly used in the treatment of HCC in patients with well-compensated liver diseases.

In this study, we determined that the 1-, 2-, 3-, 4- and 5-year overall survival rates after RFA and TACE treatment were 97.5%

![Figure 1. Cumulative overall survival in hepatocellular carcinoma (HCC) patients stratified by age.](image)

There was no statistically significant difference in the overall survival rate between young (<65 years old) and elderly patients (P = 0.37). The overall survival rates were not significantly correlated with body mass index (BMI) (P = 0.88).

doi:10.1371/journal.pone.0089081.g001

### Table 1. Comparison of the demographic data of younger (Age ≤65 y) and elder (Age >65 y) HCC patients.

| Parameter                    | Younger (n=442) | Elder (n=45) | p-value |
|------------------------------|-----------------|-------------|---------|
| Age (years)                  | 52±7.3          | 69±3.7      | <0.001  |
| Sex (male/female)            | 371/71          | 37/8        | 0.76    |
| Background liver diseases (HBV/HCV/others) | 388/30/25      | 35/6/3      | 0.75    |
| Naïve/recurrent              | 423/19          | 42/3        | 0.49    |
| Tumor diameter (cm)          | 2.23±1.19       | 2.31±1.20   | 0.67    |
| No. of tumors: >1/1          | 103/339         | 11/34       | 0.86    |
| BMI: ≥25/≤25                 | 24.65±3.49      | 23.66±3.47  | 0.07    |
| ALT (IU/L)                   | 38.51±26.48     | 33.20±21.49 | 0.13    |
| T-Bil (mg/L)                 | 21.49±14.09     | 18.97±8.64  | 0.08    |
| ALB (g/dL)                   | 35.83±6.82      | 35.04±5.63  | 0.39    |
| PT (%)                       | 13.19±5.59      | 12.71±1.59  | 0.18    |
| PLT (x10^4/μL)               | 97.56±65.82     | 95.93±48.13 | 0.84    |
| AFP                          | 391.79±1752.06  | 276.69±1123.42 | 0.55 |

All data are shown as mean ± standard deviation. AFP, a-fetoprotein; ALB, albumin; ALT, alanine aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; PLT, platelet; PT, prothrombin time; T-Bil, total bilirubin.
doi:10.1371/journal.pone.0089081.t001
Figure 2. Cumulative overall survival in hepatocellular carcinoma (HCC) patients stratified by naïve or recurrent (a), tumor diameter (cm) (b), number of tumors (c), albumin (ALB) (g/dL) (d), prothrombin time (PT) (e) or platelet count (PLT) (f). The tumor recurrent status, number of tumors, ALB, PT and PLT were significantly associated with poor overall survival after RFA combined with TACE for HCC. doi:10.1371/journal.pone.0089081.g002

Table 2. Factors associated with poor overall survival after RFA and TACE for HCC by univariate analysis.

| Variable                              | Case No. | Hazard Ratio (95% Confidence Interval) | p-value |
|---------------------------------------|----------|----------------------------------------|---------|
| Age: >53/≤54/y/o                      | 257/230  | 1.56 (0.8295–2.931)                    | 0.16    |
| Sex: male/female                      | 408/79   | 1.33 (0.5712–3.083)                    | 0.51    |
| Background liver diseases (HBV/HCV/others) | 423/36/28 | 0.33 (0.098–1.109)                    | 0.07    |
| Naïve/recurrent                        | 465/22   | 1.5×10⁻⁵ (3.01×10⁻⁷–7.78×10⁻⁵)        | <0.0001 |
| Tumor size: >3 cm/≤3 cm                | 71/416   | 1.13 (0.4887–2.600)                    | 0.77    |
| No. of tumors: >1/1                   | 114/373  | 0.45 (0.2217–0.9328)                   | 0.03    |
| BMI: ≥25/＜25                          | 207/280  | 1.05 (0.5505–1.998)                    | 0.88    |
| ALT (IU/L): >38/≤38                   | 158/329  | 1.13 (0.5824–2.207)                    | 0.71    |
| T-Bil (mg/L): >21/≤21                 | 178/309  | 1.01 (0.5230–1.958)                    | 0.97    |
| ALB (g/dL): >35/≤35                   | 260/227  | 1.98 (1.056–3.754)                     | 0.03    |
| PT (s): ≥13/≤13                       | 172/315  | 0.37 (0.1939–0.7106)                   | 0.003   |
| PLT (x10⁴/μL): >97/≤97                 | 182/305  | 1.87 (0.9764–3.585)                    | 0.05    |
| AFP: >350/≤350                        | 79/408   | 0.72 (0.2701–1.901)                    | 0.50    |

All data are shown as mean ± standard deviation. AFP, a-fetoprotein; ALB, albumin; ALT, alanine aminotransferase; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; PLT, platelet; PT, prothrombin time; T-Bil, total bilirubin.

doi:10.1371/journal.pone.0089081.t002
(47/487), 89.4% (277/310), 84.2% (181/215), 80.4% (150/186) and 78.2% (141/177), respectively. Shibata et al. [34] reported the overall survival rates of the 1-, 2-, 3- and 4-year, from combined TACE and RFA (n = 46) compared with RFA alone (n = 43) in patients with Child’s A or B cirrhosis and resectable HCC with ≤3 nodules smaller than 3 cm. The overall survival rates were 100, 100, 84.8 and 72.7%, respectively, in the combined treatment group and 100, 88.8, 84.5 and 74.0%, respectively, in the RFA group (p = 0.515). Thus, the authors considered that combined treatment of small-sized (≤3 cm) HCCs, and they thought the combination of treatments may not be necessary. Morimoto et al. [28] reported the 3-year survival rates of the patients in the RFA and TACE-RFA groups were 80 and 93%, respectively (p = 0.369) from a midterm outcomes of a randomized controlled trial comparing the efficacy of TACE combined with RFA with RFA alone for the treatment of intermediate-sized HCC. Recently, Peng et al. [35] reported that the 1-, 3-, and 4-year overall survivals for the TACE-RFA group in the treatment of HCC were 92.6%, 84.8% and 72.7%, respectively, in the RFA group, they were 85.3%, 59%, and 45.0%, respectively. They concluded that TACE-RFA was superior to RFA alone in improving survival for patients with HCC less than 7 cm. In our study, tumor size did not significantly impact the overall survival indicating that RFA combined with TACE for HCC treatment is the same effective for big sized tumors (>3 cm) as for small sized tumors (≤3 cm). Although the role of combined RFA with TAE or TACE in the treatment of HCC has not completely determined, the published results and our current study provide evidence for the rationale for using combined RFA with TAE or TACE in the future treatment of primary HCC. It should be noted that yttrium-90 microspheres as radioactive particles are also increasingly employed for treating patients with unresectable HCC, which is called radioembolization [36,37]. Further studies will be needed to identify which option is the best for treating patients with unresectable HCC.

Since previous studies reported younger HCC patients have better overall survival and lower recurrence rate after RFA compared with elder patients [9], we examined whether or not age also plays a role in this cohort. We found the overall survival rates were not significantly higher in younger than in elderly HCC patients. Since previous studies showed that the 4-year cumulative local recurrence rate after RFA in the caudate group and the non-caudate group was 22.3% and 4.5%, respectively (P<0.001) [10], we also determined whether or not RFA combined with TACE for HCC treatment is as effective for HCC in the caudate lobe as it is for HCC at other sites in the liver. We did not find any significant differences between the caudate group and the non-caudate group and the overall survival rates were not significantly changed between the two groups.

In conclusion, this study identified that tumor recurrent status, number of tumors, ALB, PT and PLT were significantly associated with poor overall survival after RFA and TACE for HCC. We did not observe any significant difference in the overall survival between younger and elderly patients, or patients with caudate and non-caudate HCC. We also found that tumor size or patient age does not affect the overall survival. This is different from another study reporting that the tumor size and number were significant independent factors affecting recurrence-free survival [38]. In order to achieve better efficacy for treating patients with unresectable HCC, Further studies will be needed to identify the

| Parameter | Caudate group (n=19) | Non-caudate group (n=468) | p-value |
|-----------|----------------------|--------------------------|---------|
| Age (years) | 55±8.5 | 54±8.6 | 0.48 |
| Sex (male/female) | 16/3 | 392/76 | 0.94 |
| Background liver diseases (HBV/HCV/others) | 16/2/1 | 407/34/27 | 0.59 |
| Naïve/recurrent | 18/1 | 447/21 | 0.79 |
| Tumor diameter (cm) | 2.34±1.33 | 2.47±1.16 | 0.64 |
| No. of tumors: >1/1 | 4/15 | 110/358 | 0.80 |
| ALT (IU/L) | 46.05±33.23 | 37.69±25.75 | 0.29 |
| T-Bil (mg/L) | 25.07±15.48 | 21.11±13.62 | 0.28 |
| ALB (g/dL) | 34.16±4.90 | 35.82±6.78 | 0.17 |
| PT (%) | 13.02±2.07 | 13.15±5.45 | 0.79 |
| PLT (x10^6/µL) | 100.12±73.32 | 97.21±64.09 | 0.87 |
| AFP | 234.27±440.65 | 387.4±1735.7 | 0.24 |

All data are shown as mean ± standard deviation. AFP, a-fetoprotein; ALB, albumin; ALT, alanine aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; PT, prothrombin time; T-Bil, total bilirubin. doi:10.1371/journal.pone.0089081.t003
prognostic factors that could potentially affect the outcome of this combination therapy.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
2. Venoak AP, Papandreou G, Farina J, de Guevara LL. (2010) The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15 Suppl 4: 5–13.
3. Lencioni R, Chen XP, Dagher L, Venoak AP. (2010) Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can we improve outcomes? Oncologist 15 Suppl 4: 42–52.
4. Fortune BE, Unman V, Gilliland T, Emre S (2013) Liver transplantation for hepatocellular carcinoma: a surgical perspective. J Clin Gastroenterol 47 Suppl: S87–S92.
5. Raut S, Di Stasi M, Bucarini E, Quaretto P, Garagnati F, et al. (1996) Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 167: 759–768.
6. Curley SA, Izzo F, Ellis LM, Nicolaus Vauthy J, Vallone P (2000) Radiofrequency ablation of hepatic cancer in 110 patients with cirrhosis. Ann Surg 232: 381–391.
7. Huang GT, Lee PH, Tsang YM, Lai MY, Yang PM, et al. (2005) Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 242: 36–42.
8. N’Kontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, et al. (2009) Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 50: 1475–1483.
9. Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, et al. (2012) Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy. J Clin Gastroenterol 46: 62–70.
10. Nishigaki Y, Tomita E, Hayashi H, Suzuki Y, Iritani S, et al. (2013) Efficacy and safety of radiofrequency ablation for hepatocellular carcinoma in the caudate lobe of the liver. Hepatol Res 43: 467–474.
11. Tateishi R, Shima S, Teratani T, Obi S, Sato S, et al. (2005) Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 103: 1201–1209.
12. Maluccio MA, Covey AM, Porat LB, Schulbert J, Brody LA, et al. (2008) Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 19: 862–869.
13. Wang S, Zhuang L, Meng Z (2013) Hepatocellular Carcinoma More Than 3 cm in Diameter: A Systematic Review of Transcatheter Arterial Chemoembolization Plus Percutaneous Ethanol Injection versus Transcatheter Arterial Chemoembolization Alone. ISRN Gastroenterol 2013: 528924.
14. Idee JM, Guina B. (2013) Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review. Crit Rev Oncol Hematol 3: 00153–00154.
15. Ni JY, Liu SS, Xu LF, Sun HL, Chen YT (2013) Meta-analysis of radiofrequency ablation in combination with transcatheter chemoembolization for hepatocellular carcinoma. World J Gastroenterol 19: 3872–3881.
16. Choi SB, Kim KS, Park YN, Choi JS, Lee WJ, et al. (2009) The efficacy of hepatic resection after neoadjuvant transcatheter chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size. J Korean Med Sci 24: 242–247.
17. Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD, Kan Z (2006) Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 41: 516–521.
18. Georgiades CS, Hong K, Gewitz JD (2000) Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J 14: 117–122.
19. Cheng BQ, Jia CQ, Lin CT, Fan W, Wang QL, et al. (2008) Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial JAMA 299: 1669–1677.
20. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020–1022.
21. WHO (2013) Definition of an older or elderly person. Available: http://www.who.int/healthinfo/ageingdefinition/en/.
22. Seki T, Tamae T, Nakagawa T, Inamura M, Nishimura A, et al. (2000) Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer 89: 1245–1251.
23. Fong Y, Sun RL, Jarnagin W, Blumgart LH (1999) An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 229: 790–799; discussion 799–800.
24. Erolaani G, Grazi GL, Raviaoli M, Del Gaudio M, Gardini A, et al. (2003) Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 237: 536–543.
25. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, et al. (2001) Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 234: 63–70.
26. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, et al. (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243: 321–328.
27. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, et al. (2000) Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 47: 82–89.
28. Rossi S, Ravetta V, Rosa L, Ghiottoni G, Viera FT, et al. (2011) Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology 53: 136–147.
29. Guan YS, He Q, Wang MQ, et al. (2002) Transcatheter arterial chemoembolization: history for more than 30 years. ISRN Gastroenterol 2012: 480656.
30. Takayasu K (2012) Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. Jpn J Clin Oncol 42: 247–253.
31. Marelli L, Stigliano R, Triantos C, Senolo M, Cholongitas E, et al. (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30: 6–25.
32. Rossi S, Garbagnati F, Lencioni R, Allgair HP, Marchiano A, et al. (2000) Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 217: 119–126.
33. Seki T, Wakabayashi M, Nakagawa T, Ito T, Shiro T, et al. (1994) Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 74: 817–825.
34. Shibata T, Iosha H, Hirokawa Y, Arriazu S, Shimada K, et al. (2009) Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? RadioLOGY 232: 985–993.
35. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, et al. (2013) Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 31: 426–432.
36. Kim DY, Park BJ, Kim YH, Han KH, Cho SB, et al. (2013) Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma: A Multicenter Prospective Study. Am J Clin Oncol. 37. Kim YH, Kim do Y (2013) Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know. Oncology 84 Suppl: 34–39.
38. Fujimoto M, Takaki H, Nakatsuka A, Uraki J, Yamanaka T, et al. (2013) Survival with up to 10-year follow-up after combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma: single-center experience. J Vasc Interv Radiol 24: 653–666.

Author Contributions

Conceived and designed the experiments: HX WW HW. Performed the experiments: HX WW HW RQ BY CL. Analyzed the data: HX WW HW YG BX. Contributed reagents/materials/analysis tools: WA WM. Wrote the paper: WW HW.